Infants and children with tachycardia

Natural history and drug administration

Peter P. Karpawich, Michael D. Pettersen, Pooja Gupta, Nishant Shah

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Tachyarrhythmias can occur at any age from the developing fetus through adulthood. However, in deference to adult-onset ischemic cardiac issues, abnormal heart rhythms occurring in the young are often due to developmental alterations of the cardiac conduction tissue, genetically-inherited changes of myocardial celludar ion membrane properties and both pre- andpost-surgical repair of associated structural congenital heart anatomical defects. And different from adults, abnormal rhythms occurring in the young can spontaneously disappear with progressive patient growth. Both supra- and ventricular tachyarrhythmias occur in the young although atrial rhythm abnormalities far exceed those of the ventricle. In both, pharmacologic therapies to alter tissue conduction and refractoriness remain the mainstay for initial intervention in the infant and young child, reserving more invasive and potentially harmful ablation therapies for drug-refractory cases. The purpose of the review is to present common and uncommon tachyarrhythmias which can occur in the fetus and throughout infancy. Emphasis will be placed on their electrocardiographic identification, recognition of any associated structural congenital heart defects and recommended pharmacologic management. Drug therapies will be divided according to mechanism of action and discussions of which particular agent is potentially best-suited to treat which specific tachyarrhythmia. A listing of current pharmacologic agents used in the young with appropriate dosages is included.

Original languageEnglish (US)
Pages (from-to)743-752
Number of pages10
JournalCurrent Pharmaceutical Design
Volume14
Issue number8
DOIs
StatePublished - Mar 2008

Fingerprint

Natural History
Tachycardia
Congenital Heart Defects
Pharmaceutical Preparations
Fetus
Drug Therapy
Ions
Membranes
Growth
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Karpawich, Peter P. ; Pettersen, Michael D. ; Gupta, Pooja ; Shah, Nishant. / Infants and children with tachycardia : Natural history and drug administration. In: Current Pharmaceutical Design. 2008 ; Vol. 14, No. 8. pp. 743-752.
@article{c26658f57dab49aeac90040d22a11012,
title = "Infants and children with tachycardia: Natural history and drug administration",
abstract = "Tachyarrhythmias can occur at any age from the developing fetus through adulthood. However, in deference to adult-onset ischemic cardiac issues, abnormal heart rhythms occurring in the young are often due to developmental alterations of the cardiac conduction tissue, genetically-inherited changes of myocardial celludar ion membrane properties and both pre- andpost-surgical repair of associated structural congenital heart anatomical defects. And different from adults, abnormal rhythms occurring in the young can spontaneously disappear with progressive patient growth. Both supra- and ventricular tachyarrhythmias occur in the young although atrial rhythm abnormalities far exceed those of the ventricle. In both, pharmacologic therapies to alter tissue conduction and refractoriness remain the mainstay for initial intervention in the infant and young child, reserving more invasive and potentially harmful ablation therapies for drug-refractory cases. The purpose of the review is to present common and uncommon tachyarrhythmias which can occur in the fetus and throughout infancy. Emphasis will be placed on their electrocardiographic identification, recognition of any associated structural congenital heart defects and recommended pharmacologic management. Drug therapies will be divided according to mechanism of action and discussions of which particular agent is potentially best-suited to treat which specific tachyarrhythmia. A listing of current pharmacologic agents used in the young with appropriate dosages is included.",
author = "Karpawich, {Peter P.} and Pettersen, {Michael D.} and Pooja Gupta and Nishant Shah",
year = "2008",
month = "3",
doi = "10.2174/138161208784007734",
language = "English (US)",
volume = "14",
pages = "743--752",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

Infants and children with tachycardia : Natural history and drug administration. / Karpawich, Peter P.; Pettersen, Michael D.; Gupta, Pooja; Shah, Nishant.

In: Current Pharmaceutical Design, Vol. 14, No. 8, 03.2008, p. 743-752.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Infants and children with tachycardia

T2 - Natural history and drug administration

AU - Karpawich, Peter P.

AU - Pettersen, Michael D.

AU - Gupta, Pooja

AU - Shah, Nishant

PY - 2008/3

Y1 - 2008/3

N2 - Tachyarrhythmias can occur at any age from the developing fetus through adulthood. However, in deference to adult-onset ischemic cardiac issues, abnormal heart rhythms occurring in the young are often due to developmental alterations of the cardiac conduction tissue, genetically-inherited changes of myocardial celludar ion membrane properties and both pre- andpost-surgical repair of associated structural congenital heart anatomical defects. And different from adults, abnormal rhythms occurring in the young can spontaneously disappear with progressive patient growth. Both supra- and ventricular tachyarrhythmias occur in the young although atrial rhythm abnormalities far exceed those of the ventricle. In both, pharmacologic therapies to alter tissue conduction and refractoriness remain the mainstay for initial intervention in the infant and young child, reserving more invasive and potentially harmful ablation therapies for drug-refractory cases. The purpose of the review is to present common and uncommon tachyarrhythmias which can occur in the fetus and throughout infancy. Emphasis will be placed on their electrocardiographic identification, recognition of any associated structural congenital heart defects and recommended pharmacologic management. Drug therapies will be divided according to mechanism of action and discussions of which particular agent is potentially best-suited to treat which specific tachyarrhythmia. A listing of current pharmacologic agents used in the young with appropriate dosages is included.

AB - Tachyarrhythmias can occur at any age from the developing fetus through adulthood. However, in deference to adult-onset ischemic cardiac issues, abnormal heart rhythms occurring in the young are often due to developmental alterations of the cardiac conduction tissue, genetically-inherited changes of myocardial celludar ion membrane properties and both pre- andpost-surgical repair of associated structural congenital heart anatomical defects. And different from adults, abnormal rhythms occurring in the young can spontaneously disappear with progressive patient growth. Both supra- and ventricular tachyarrhythmias occur in the young although atrial rhythm abnormalities far exceed those of the ventricle. In both, pharmacologic therapies to alter tissue conduction and refractoriness remain the mainstay for initial intervention in the infant and young child, reserving more invasive and potentially harmful ablation therapies for drug-refractory cases. The purpose of the review is to present common and uncommon tachyarrhythmias which can occur in the fetus and throughout infancy. Emphasis will be placed on their electrocardiographic identification, recognition of any associated structural congenital heart defects and recommended pharmacologic management. Drug therapies will be divided according to mechanism of action and discussions of which particular agent is potentially best-suited to treat which specific tachyarrhythmia. A listing of current pharmacologic agents used in the young with appropriate dosages is included.

UR - http://www.scopus.com/inward/record.url?scp=44349147237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349147237&partnerID=8YFLogxK

U2 - 10.2174/138161208784007734

DO - 10.2174/138161208784007734

M3 - Review article

VL - 14

SP - 743

EP - 752

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 8

ER -